Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
In patients with HER2-positive early breast cancer who have residual disease after receiving neoadjuvant treatment with HP, the continued administration of HP can achieve therapeutic effects comparable to those of T-DM1, without significant complications.
Authors
- Yushuai Yu (ORCID: https://orcid.org/0009-0002-2494-4981)
- Xin Wang (ORCID: https://orcid.org/0000-0001-9325-3194)
- Junxiao Wang (ORCID: https://orcid.org/0000-0001-7462-2716)
- Qisheng Lin
Institutions
- Fujian University of Traditional Chinese Medicine (CN)
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Sanming University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12957-025-03909-9
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00